Severe Alopecia Areata study: Upadacitinib
Official title A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
ClinicalTrials.gov ID: NCT07772492
What this study is testing
What is Upadacitinib?
an investigational oral medicine being studied as a potential treatment for severe alopecia areata in pediatric patients is designed to inhibit Janus kinase (JAK) enzymes to reduce inflammation
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to learn whether upadacitinib is safe and works to reduce hair loss in children with severe alopecia areata.
- Who it's for
- Children ages 6 to under 18 who have severe alopecia areata (at least 50% scalp hair loss).
- What's involved
- Participants will take an oral dose of upadacitinib or a matching placebo each day (or twice daily) and attend regular clinic visits for exams, blood tests, side‑effect checks, and questionnaires.
- Time commitment
- The trial lasts about 160 weeks (roughly 3 years) and includes a screening period, multiple treatment phases, and a final follow‑up visit.
- Phase 3: a large, late-stage study
- Time commitment: about 160 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 6 to 17
You may be able to join if
- Participants must have a diagnosis of severe alopecia areata with SALT score \>= 50 scalp hair loss at Screening and Baseline
- No spontaneous scalp hair regrowth over the past 6 months
- Participants will have current episode of alopecia areata of less than 8 years
You likely can't join if
- Participants must not have a current diagnosis of primarily diffuse type of alopecia areata
- Participants must not have a diagnosis of other types of alopecia that would interfere with evaluation of alopecia areata, including but not limited...
- Participants must not have a diagnosis of other types of inflammatory scalp, eyebrow, or eyelash disorders that would interfere with evaluation of...
The study team makes the final eligibility decision.
Where it is enrolling
- Los Angeles, California, United States
- Miami, Florida, United States
- Meridian, Idaho, United States
- Indianapolis, Indiana, United States
- Omaha, Nebraska, United States
- Fairborn, Ohio, United States
- El Paso, Texas, United States
- San Antonio, Texas, United States
- Norfolk, Virginia, United States
- Kogarah, New South Wales, Australia
- Coorparoo, Queensland, Australia
- East Melbourne, Victoria, Australia
- Osaka, Osaka, Japan
- Taipei, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 160 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 6 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Los Angeles, California, United States; Miami, Florida, United States; Meridian, Idaho, United States; Indianapolis, Indiana, United States; Omaha, Nebraska, United States; Fairborn, Ohio, United States and 8 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.